Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Bexion Pharmaceuticals logo — Bexion Pharmaceuticals is a mid-stage clinical company devel...

Bexion Pharmaceuticals

Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS.

Founded 2006 United States Covington, United States 27 employees Total: $18.00M Biopharma, Biotechnology +2

General Information

Company Name Bexion Pharmaceuticals
Founded Year 2006
Location United States Covington, United States
Founders / Decision Makers
Team member
Employees 27
Industries Biopharma, Biotechnology, Life Sciences +1
Business Model B2B, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Bexion Pharmaceuticals. To contact Bexion Pharmaceuticals, visit bexionpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Bexion Pharmaceuticals compare?

A PDF of Bexion Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Bexion Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Bexion Pharmaceuticals

Bexion Pharmaceuticals, founded in 2006, is a United States-based company operating at the forefront of the Biopharma, Biotechnology, Life Sciences, and Pharmaceutical industries. The company has carved out a niche in developing transformative treatments within the oncology and central nervous system (CNS) sectors.

The core asset propelling Bexion Pharmaceuticals forward is BXQ-350, a groundbreaking S1P modulator that positions the company to make significant strides in oncological therapies. As a mid-stage clinical company, Bexion is leveraging the deep industry experience of its biotech leadership team to expedite its promising pipeline.

The firm attracted a $16.60M Series B investment on 30 April 2019, underscoring investor confidence in its potential to become a leader in the biotech and pharmaceutical landscape.

Business keywords: Oncology, CNS (Central Nervous System), S1P Modulator, BXQ-350, Tumor Targeting, Phosphatidylserine Patches, Acid Sphingomyelinase Activation, Ceramide Generation, Caspase Elevation, Biopharmaceutical, Clinical Development, Novel Mechanism of Action, Tumor Neovasculature, Apoptosis Induction

Services & Products

Development of cancer therapies
Clinical-stage drug development
Phase 1b/2a clinical trials
Biologic therapy research

Target Customers

Cancer patients Oncologists Clinical researchers Biopharmaceutical investors

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $1.40M 1
The Michael J. Fox Foundation for Parkinson's Research
The Michael J. Fox Foundation for Parkinson's Research
01 Nov 2024
Early VC $16.60M -
01 Apr 2019
Seed Undisclosed 1
Mammoth View (KSTC)
01 Nov 2008
Spinout Undisclosed 1
Enter Capital
Enter Capital
01 Mar 2006

Bexion Pharmaceuticals Alternatives & Competitors

View All Alternatives
Bexion Pharmaceuticals vs
Arcellx
Arcellx United States

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

Acquired
121 employees
Biopharma, Biotechnology
Bexion Pharmaceuticals vs
Bicara Therapeutics
Bicara Therapeutics United States

Pioneering bifunctional antibodies for targeted tumor modulation

IPO
123 employees
Biopharma, Biotechnology
Bexion Pharmaceuticals vs
Alterome Therapeutics, Inc
Alterome Therapeutics, Inc United States

To Life!

Series B
43 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Bexion Pharmaceuticals

Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS.
Bexion Pharmaceuticals was founded in 2006.
Bexion Pharmaceuticals is headquartered in Covington, United States.
Bexion Pharmaceuticals operates in Biopharma, Biotechnology, Life Sciences and Pharmaceutical. Its work centres on Oncology, CNS (Central Nervous System), S1P Modulator and BXQ-350. Its customers include Cancer patients, Oncologists and Clinical researchers.
Bexion Pharmaceuticals has a B2B and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Bexion Pharmaceuticals has approximately 27 employees.
Bexion Pharmaceuticals has completed 4 funding rounds, raising a total of $18.00M.
Bexion Pharmaceuticals offers: Development of cancer therapies, Clinical-stage drug development, Phase 1b/2a clinical trials, Biologic therapy research.
Top alternatives and competitors to Bexion Pharmaceuticals include Arcellx, Bicara Therapeutics, Alterome Therapeutics, Inc, Cybrexa Therapeutics, Vertero Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bexion Pharmaceuticals and Arcellx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bexion Pharmaceuticals, https://bouncewatch.com/company/bexion-pharmaceuticals, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout